𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The rationale for deltanoids in therapy for myeloid leukemia: Role of KSR–MAPK–C/EBP pathway

✍ Scribed by George P. Studzinski; Xuening Wang; Yan Ji; Qing Wang; Yingyu Zhang; Andrzej Kutner; Jonathan S. Harrison

Book ID
116697667
Publisher
Elsevier Science
Year
2005
Tongue
English
Weight
643 KB
Volume
97
Category
Article
ISSN
0960-0760

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Practical advice for determining the rol
Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia
✍ Elias Jabbour; Susan Branford; Giuseppe Saglio; Dan Jones; Jorge E. Cortes; Hago 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 288 KB 👁 1 views

## Abstract Data demonstrating the superiority of nilotinib over imatinib in the frontline treatment of chronic myeloid leukemia (CML) and ongoing studies with dasatinib and bosutinib are rapidly changing the treatment landscape for CML. In this review, the authors discuss currently available thera

JNK1/c-Jun and p38α MAPK/ATF-2 pathways
JNK1/c-Jun and p38α MAPK/ATF-2 pathways are responsible for upregulation of Fas/FasL in human chronic myeloid leukemia K562 cells upon exposure to Taiwan cobra phospholipase A2
✍ Ku-Chung Chen; Yi-Ling Chiou; Long-Sen Chang 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 421 KB

## Abstract Fas and FasL expression upregulation was found in human leukemia K562 cells upon exposure to __Naja naja atra__ phospholipase A~2~ (PLA~2~). PLA~2~ treatment induced an increase in intracellular Ca^2+^ ([Ca^2+^]i) and ROS generation levels, leading to activation of p38 MAPK and JNK. Sup